Archives of Gynecology and Obstetrics

, Volume 275, Issue 4, pp 223–229 | Cite as

Interstitial cystitis

Review

Abstract

Interstitial cystitis is an enigmatic and frustrating condition to manage as a physician and to cope with as a patient. Traditionally, it has been defined as a chronic sterile inflammatory disease of the bladder of unknown aetiology. However, the International Continence Society prefers the term painful bladder syndrome and it has been decided to follow this terminology and refer to the disease as painful bladder syndrome/interstitial cystitis (PBS/IC). The condition is characterized by bladder pain, urinary frequency, urgency and nocturia. The quality of life of patients with PBS/IC is significantly degraded. Its aetiology is unknown, but might involve microbiologic, immunologic, mucosal, neurogenic and other yet unidentified agents. History, physical examination, urine analysis and culture as well as cystoscopy and hydrodistension are useful diagnostic tools but the final diagnosis tends to be a diagnosis of exclusion. This article will review the major theories of aetiology for PBS/IC and discuss diagnosis as well as the current treatment options with relevance to the proposed aetiologies.

Keywords

Cystitis Interstitial Aetiology Diagnosis Treatment 

References

  1. 1.
    Abrams PH, Cardozo L, Fall M et al (2002) The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn 21:167–178PubMedCrossRefGoogle Scholar
  2. 2.
    Sant GR (1997) Interstitial cystitis. Lippincott-Raven, Philadelphia, pp 284Google Scholar
  3. 3.
    Clemens JQ, Meenan RT, Rosetti MC, Gao SY, Calhoun EA (2005) Prevalence and incidence of interstitial cystitis in a managed care population. J Urol 173(1):98–102PubMedCrossRefGoogle Scholar
  4. 4.
    Held PJ, Hanno PH, Wein AJ et al (1990) Epidemiology of interstitial cystitis: 2. In: Hanno PM, Staskin DR, Krane RJ et al (eds) Interstitial cystitis. Springer, Berlin Heidelberg New York, pp 29–48Google Scholar
  5. 5.
    Hanno PM (1994) Diagnosis of interstitial cystitis. Urol Clin North Am 21:63–66PubMedGoogle Scholar
  6. 6.
    Domingue GJ, Ghoniem GM, Human L et al (1996) Bacteriology of urinary bladder tissue and urine in interstitial cystitis. J Urol 156:1843–1845CrossRefGoogle Scholar
  7. 7.
    Keay S, Schwalbe R, Trifillis A et al (1995) A prospective study of micro organisms in urine and bladder biopsies from interstitial cystitis patients and controls. Urology 45:223–229PubMedCrossRefGoogle Scholar
  8. 8.
    Warren JW, Horne LM, Hebel JR et al (2000) Pilot study of sequential oral antibiotics for the treatment of interstitial cystitis. J Urol 163:1685–1688PubMedCrossRefGoogle Scholar
  9. 9.
    Parsons CL (1990) Role of toxic urine in interstitial cystitis. J Urol 143:373AGoogle Scholar
  10. 10.
    Wein AJ, Broderick GA (1994) Interstitial cystitis: current and future approaches to diagnosis and treatment. Urol Clin North Am 21:153–161PubMedGoogle Scholar
  11. 11.
    Parsons CL, Zupkas P, Parsons JK (2001) Intravesical potassium sensitivity in patients with interstitial cystitis and urethral syndrome. Urology 57:428–433PubMedCrossRefGoogle Scholar
  12. 12.
    Anderson JB, Parivar F, Lee G et al (1989) The enigma of interstitial cystitis—an autoimmune disease? Br J Urol 63:58–63PubMedGoogle Scholar
  13. 13.
    Ochs RL, Stein TW Jr, Peebles CL et al (1994) Autoantibodies in interstitial cystitis. J Urol 151:587–592PubMedGoogle Scholar
  14. 14.
    Joniken EJ, Alfthan OS, Oravisto KJ (1972) Anti-tissue antibodies in interstitial cystitis. Clin Exp Immunol 11:333–339Google Scholar
  15. 15.
    Sant GR, Theoharides TC, El-Mansoury M et al (1993) Mast cells are increased in number and activation in interstitial cystitis. J Urol 149(4/2):507AGoogle Scholar
  16. 16.
    Wesselmann U (2001) Interstitial cystitis: a chronic visceral pain syndrome. Urology 57:32–39PubMedCrossRefGoogle Scholar
  17. 17.
    Peeker R, Aldenborg F, Dahlstrom A et al (2000) Increased tyrosine hydroxylase immunoreactivity in bladder tissue from patients with classic and nonulcer interstitial cystitis. J Urol 163:1112–1115PubMedCrossRefGoogle Scholar
  18. 18.
    Pang X, Cotreau-Bibbo MM, Sant GR et al (1995) Bladder mast cell expression of high affinity estrogen receptors in patients with interstitial cystitis. Br J Urol 75:154–161PubMedCrossRefGoogle Scholar
  19. 19.
    Messing EM (1987) The diagnosis of interstitial cystitis. Urology 29(4 Suppl):4–7PubMedGoogle Scholar
  20. 20.
    Messing E, Pauk D, Schaeffer A et al (1997) Associations among cystoscopic findings and symptoms and physical examination findings in women enrolled in the Interstitial Cystitis Data Base (ICDB) Study. Urology 49(5A Suppl):81–85PubMedCrossRefGoogle Scholar
  21. 21.
    Erickson DR (2001) Urine markers of interstitial cystitis. Urology 57:15–21PubMedCrossRefGoogle Scholar
  22. 22.
    Logadottir YR, Ehrn I, Fall M et al (2004) Intravesical nitric oxide production discriminates between classic and nonulcer interstitial cystitis. J Urol 171:1148–1150PubMedCrossRefGoogle Scholar
  23. 23.
    Rovner E, Propert KJ, Brensinger C et al (2000) Treatments used in women with interstitial cystitis: the Interstitial Cystitis Data Base (ICDB) study experience. Urology 56:940–945PubMedCrossRefGoogle Scholar
  24. 24.
    Hanno PH (1994) Amitriptyline in the treatment of interstitial cystitis. Urol Clin North Am 21:89–92PubMedGoogle Scholar
  25. 25.
    Van Ophoven A, Pokupic S, Heinecke A, Hertle L (2004) A prospective, randomised, placebo-controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis. J Urol 172(2):533–536PubMedCrossRefGoogle Scholar
  26. 26.
    Theoharides TC, Sant GR (1997) Hydroxyzine therapy for interstitial cystitis. Urology 49(5A suppl):108–110PubMedCrossRefGoogle Scholar
  27. 27.
    Chiang G, Patra P, Letourneau R et al (2000) Pentosanpolysulfate inhibits mast cell histamine secretion and intracellular calcium ion levels: an alternative explanation of its beneficial effect in interstitial cystitis. J Urol 164:2119–2125PubMedCrossRefGoogle Scholar
  28. 28.
    Sant GR, Propert KJ, Hanno PM et al (2003) A pilot clinical trial of oral pentosan polysulfate and oral hydroxyzine in patients with interstitial cystitis. J Urol 170(3):810–815PubMedCrossRefGoogle Scholar
  29. 29.
    Sairanen J, Tammela TL, Leppilahti M et al (2005) Cyclosporine A and pentosan polysulfate sodium for the treatment of interstitial cystitis: a randomized comparative study. J Urol 174(6):2235–2238PubMedCrossRefGoogle Scholar
  30. 30.
    Nickel JC (2003) Interstitial cystitis: an elusive clinical target? J Urol 170:816–817PubMedCrossRefGoogle Scholar
  31. 31.
    Melchior D, Packer CS, Johnson TC, Kaefer M (2003) Dimethyl sulfoxide: does it change the functional properties of the bladder wall? J Urol 170:253–258PubMedCrossRefGoogle Scholar
  32. 32.
    Peters K, Diokno A, Steinert B et al (1997) The efficacy of intravesical TICE strain bacillus Calmette–Guérin in the treatment of interstitial cystitis: a double-blind, prospective, placebo controlled trial. J Urol 157:2090–2094PubMedCrossRefGoogle Scholar
  33. 33.
    Mayer R, Propert KG, Peters KM et al (2005) A randomized controlled trial of intravesical bacillus Calmette–Guerin for treatment refractory interstitial cystitis. J Urol 173(4):1186–1191PubMedCrossRefGoogle Scholar
  34. 34.
    Hanno PM (1998) Interstitial cystitis and related diseases. In: Walsh PC, Retik A, Vaughn D et al (eds) Campbell’s urology. WB Saunders, Philadelphia, pp 631–662Google Scholar
  35. 35.
    Oyama IA, Rejba A, Lukban JC et al (2004) Modified Thiele massage as therapeutic intervention for female patients with interstitial cystitis and high-tone pelvic floor dysfunction. Urology 64(5):862–865PubMedCrossRefGoogle Scholar
  36. 36.
    Chai TC, Zhang C-O, Warren JW, Keay SK (2000) Percutaneous sacral third nerve root neurostimulation improves symptoms and normalizes urinary HB-EGF levels and antiproliferative activity in patients with interstitial cystitis. Urology 55:643–646PubMedCrossRefGoogle Scholar
  37. 37.
    Maher CF, Carey MP, Dwyer PL, Schluter PL (2001) Percutaneous sacral nerve root neuromodulation for intractable interstitial cystitis. J Urol 165:884–886PubMedCrossRefGoogle Scholar
  38. 38.
    Peters KM, Carey JM, Konstandt DB (2003) Sacral neuromodulation for the treatment of refractory interstitial cystitis: outcomes based on technique. Int Urogynecol J Pelvic Floor Dysfunct 14(4):223–228PubMedCrossRefGoogle Scholar
  39. 39.
    Chai TC, Zhang C-O, Shoenfelt JL et al (2000) Bladder stretch alters urinary heparin-binding epidermal growth factor and antiproliferative factor in patients with interstitial cystitis. J Urol 163:1440–1444PubMedCrossRefGoogle Scholar
  40. 40.
    Glemain P, Riviere C, Lenomand L et al (2002) Prolonged hydrodistension of the bladder for symptomatic treatment of interstitial cystitis: efficacy at 6 months and 1 year. Eur Urol 41:79–84PubMedCrossRefGoogle Scholar
  41. 41.
    Moldwin RM, Sant GR (2002) Interstitial cystitis: a pathophysiology and treatment update. Clin Obstet Gynecol 45:259–272PubMedCrossRefGoogle Scholar
  42. 42.
    Elzawahri A, Bissada NK, Herchorn S et al (2004) Urinary conduit formation using a retuularized bowel from continent urinary diversion or intestinal augmentations. II: does it have a role in patients with interstitial cystitis? J Urol 171:1559–1562PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  1. 1.Department of Obstetrics & GynaecologyNorth Manchester General HospitalManchesterUK
  2. 2. SurreyUK

Personalised recommendations